Kelsy Ketchum

The company offers a handheld electrochemical analyzer and its S1 infection panel that simultaneously tests for procalcitonin, lactate, and C-reactive protein.

The team added an RNA binding domain into the CRISPR-Cas13a protein to enhance the sensitivity of their COVID-19 assay. 

Two new programs from the agency's RADx program launched this month are encouraging test developers to improve accessibility and utilize new technologies for at-home testing. 

The grandfathering clause of the bill would allow labs to continue using existing LDTs as long as only minor modifications are made.

The firm's portable device uses nanowires to detect biomarkers indicating traumatic brain injury or COVID-19 in two minutes.

The electrochemical test detects both the presence of SARS-CoV-2 RNA as well as virus antibodies in saliva.

The test consists of two components, a microfluidic cartridge and a handheld analyzer, and returns results in 45 minutes or less.

The team's method is based on isolating and analyzing exosomes from tears to study and validate biomarkers for different diseases.

The company anticipates launching the test in the coming weeks to help determine an individual's immunity response to COVID-19 and disease severity.

The firm's most recent research investigates how the platform could be applied to CAR-T therapy for solid tumors.